Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1625
This examiner grants 77% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17601705 | ALLOPREGNANOLONE COMPOSITIONS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18708955 | TREATMENT OF MYOTONIC DISORDERS | Non-Final OA | University of Rochester |
| 18826275 | AT2R ANTAGONISTS AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 17995914 | COMPOUNDS FOR THE TREATMENT OF SARS | Final Rejection | Purdue Research Foundation |
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | Non-Final OA | ANDREAS HETTICH GMBH & CO. KG |
| 18245210 | METHODS OF CHEMOVACCINATION AGAINST PLASMODIUM INFECTIONS | Final Rejection | The Walter and Eliza Hall Institute of Medical Research |
| 17790961 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Anima Biotech Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy